Medical breakthroughs enhance health, economy of region

Medical breakthroughs enhance health, economy of region

The recent groundbreaking ceremony in Richland Township paves a way for the establishment of the Johnstown Heart and Vascular Center in the region. The collaboration with Windber hospital represents the positive impact of the medical center on the community that would now have access to basic as well as comprehensive cardiovascular care in the growing Richland region. In the future, the Windber hospital will hold clinical trials for cancer treatment, and will further connect the research institute’s science with other Cancer MoonShot 2020 efforts across the globe to improve treatments and eventually eradicate cancer.

Read More

Altor BioScience Announces a Phase 1b/2 Clinical Trial of IL-15 Superagonist ALT-803 in Combination with Anti-PD-1 Antibody Therapy for Advanced / Metastatic Non-Small Cell Lung Ca

Altor BioScience Announces a Phase 1b/2 Clinical Trial of IL-15 Superagonist ALT-803 in Combination with Anti-PD-1 Antibody Therapy for Advanced / Metastatic Non-Small Cell Lung Ca

Altor BioScience Corporation (Altor), a leading developer of cancer immunotherapeutics, announced enrollment is complete for the first cohort in a Phase 1b/2 trial using ALT-803, a proprietary interleukin-15 (IL-15) superagonist protein complex, in combination with the approved anti-PD-1 antibody (Ab) nivolumab (Opdivo®; Bristol-Myers Squibb) for patients with pre-treated, advanced, or metastatic non-small cell lung cancer (NSCLC). This Investigator-Sponsored Trial is being conducted under the direction of John Wrangle, M.D., M.P.H., at the Medical University of South Carolina (MUSC).

Read More

NantHealth Announces Commercial Availability of GPS Cancer™ and Launch of GPS Cancer Browser on a Secure Mobile Platform at the 2016 American Society of Clinical Oncology Annual Meeting

NantHealth, Inc. (Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, announced today the commercial availability of Genomic Proteomic Spectrometry Cancer, or GPS Cancer. Read the full press release HERE.

Read More

Dr. Patrick Soon-Shiong Shares Promising Results of Novel Adenoviral Colon Cancer Vaccine in Treating End-Stage Colon Cancer

Dr. Patrick Soon-Shiong CEO of NantWorks and founder of Cancer Moonshot 2020, announced that a novel genetically engineered adenovirus vaccine designed to treat colon cancer showed, in Phase II testing, a more than doubling of survival rate, with little to no toxicity. Promising results show some patients alive now more than five years after receiving the colon vaccine while on no other therapy.

Read full press release here.